4/6/2010

Purdue Pharma gained FDA approval to market a tamper-resistant formulation of pain drug OxyContin. The agency said the version "will likely result in less abuse by snorting or injection" because its active ingredient turns into a gel when dissolved in liquid, but it can still be abused "by simply ingesting larger doses than are recommended."

Related Summaries